DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

Elizabeth A. Griffiths, Steven D. Gore

Research output: Contribution to journalArticle

Abstract

The recently approved drugs 5-azacitidine (5AC) and 5-aza-2′-deoxyazacytidine (DAC) are in wide clinical use for the treatment of myelodysplastic syndrome (MDS) of all types and chronic myelomonocytic leukemia (CMML). These agents were developed based upon an understanding of the importance of epigenetic changes in malignancy, and they have been evaluated in randomized clinical trials, which demonstrate response rates between 20% and 40% in patients for whom no previous standard of care was available. As understanding of the epigenetic changes characteristic of the malignant phenotype improves, we are able to target other regulators of chromatin conformation that contribute to aberrant gene transcription and dysregulated cell growth. The histone deacetylase (HDAC) inhibitors belong to one class of therapeutics developed using this paradigm. Although responses using HDAC inhibitors alone in MDS have been modest, robust preclinical data drive clinical trials in which they are utilized in combination with DNA methyltransferase (DNMT) inhibitors. Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease.

Original languageEnglish (US)
Pages (from-to)23-30
Number of pages8
JournalSeminars in Hematology
Volume45
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Histone Deacetylase Inhibitors
Myelodysplastic Syndromes
Methyltransferases
Epigenomics
DNA
Leukemia, Myelomonocytic, Chronic
Azacitidine
Standard of Care
Chromatin
Therapeutics
Randomized Controlled Trials
Clinical Trials
Phenotype
Growth
Pharmaceutical Preparations
Genes
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes. / Griffiths, Elizabeth A.; Gore, Steven D.

In: Seminars in Hematology, Vol. 45, No. 1, 01.2008, p. 23-30.

Research output: Contribution to journalArticle

Griffiths, Elizabeth A. ; Gore, Steven D. / DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes. In: Seminars in Hematology. 2008 ; Vol. 45, No. 1. pp. 23-30.
@article{47968a82dad24b95aebd708d2ca2fa8c,
title = "DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes",
abstract = "The recently approved drugs 5-azacitidine (5AC) and 5-aza-2′-deoxyazacytidine (DAC) are in wide clinical use for the treatment of myelodysplastic syndrome (MDS) of all types and chronic myelomonocytic leukemia (CMML). These agents were developed based upon an understanding of the importance of epigenetic changes in malignancy, and they have been evaluated in randomized clinical trials, which demonstrate response rates between 20{\%} and 40{\%} in patients for whom no previous standard of care was available. As understanding of the epigenetic changes characteristic of the malignant phenotype improves, we are able to target other regulators of chromatin conformation that contribute to aberrant gene transcription and dysregulated cell growth. The histone deacetylase (HDAC) inhibitors belong to one class of therapeutics developed using this paradigm. Although responses using HDAC inhibitors alone in MDS have been modest, robust preclinical data drive clinical trials in which they are utilized in combination with DNA methyltransferase (DNMT) inhibitors. Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease.",
author = "Griffiths, {Elizabeth A.} and Gore, {Steven D.}",
year = "2008",
month = "1",
doi = "10.1053/j.seminhematol.2007.11.007",
language = "English (US)",
volume = "45",
pages = "23--30",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

AU - Griffiths, Elizabeth A.

AU - Gore, Steven D.

PY - 2008/1

Y1 - 2008/1

N2 - The recently approved drugs 5-azacitidine (5AC) and 5-aza-2′-deoxyazacytidine (DAC) are in wide clinical use for the treatment of myelodysplastic syndrome (MDS) of all types and chronic myelomonocytic leukemia (CMML). These agents were developed based upon an understanding of the importance of epigenetic changes in malignancy, and they have been evaluated in randomized clinical trials, which demonstrate response rates between 20% and 40% in patients for whom no previous standard of care was available. As understanding of the epigenetic changes characteristic of the malignant phenotype improves, we are able to target other regulators of chromatin conformation that contribute to aberrant gene transcription and dysregulated cell growth. The histone deacetylase (HDAC) inhibitors belong to one class of therapeutics developed using this paradigm. Although responses using HDAC inhibitors alone in MDS have been modest, robust preclinical data drive clinical trials in which they are utilized in combination with DNA methyltransferase (DNMT) inhibitors. Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease.

AB - The recently approved drugs 5-azacitidine (5AC) and 5-aza-2′-deoxyazacytidine (DAC) are in wide clinical use for the treatment of myelodysplastic syndrome (MDS) of all types and chronic myelomonocytic leukemia (CMML). These agents were developed based upon an understanding of the importance of epigenetic changes in malignancy, and they have been evaluated in randomized clinical trials, which demonstrate response rates between 20% and 40% in patients for whom no previous standard of care was available. As understanding of the epigenetic changes characteristic of the malignant phenotype improves, we are able to target other regulators of chromatin conformation that contribute to aberrant gene transcription and dysregulated cell growth. The histone deacetylase (HDAC) inhibitors belong to one class of therapeutics developed using this paradigm. Although responses using HDAC inhibitors alone in MDS have been modest, robust preclinical data drive clinical trials in which they are utilized in combination with DNA methyltransferase (DNMT) inhibitors. Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease.

UR - http://www.scopus.com/inward/record.url?scp=37549022694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549022694&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2007.11.007

DO - 10.1053/j.seminhematol.2007.11.007

M3 - Article

VL - 45

SP - 23

EP - 30

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 1

ER -